Search clinical trials for: Pertuzumab, trastuzumab

Total 1384 results

Mayo Clinic

Recruiting

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Genentech, Inc.

Completed

A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy

Metastatic Breast Cancer

United States
Hoffmann-La Roche

Completed

A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)

Early Breast Cancer

New Zealand
West German Study Group
Merck Sharp & Dohme LLC; NanoString Technologies, Inc.

Completed

A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) (Keyriched-1)

Breast Cancer

Germany
Seagen Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)

HER2 Positive Breast Cancer

United States, Taiwan, Canada, Korea, Republic of, Austria, China, Spain, Japan, France, Italy, Switzerland, Australia, Belgium, Brazil, Germany, Portugal, United Kingdom, Netherlands, Czechia, Greece, Chile, Finland, Poland
David Garcia Cinca
Fundacion Clinic per a la Recerca Biomédica

Not yet recruiting

Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial) (ELPIS)

Mammary Cancer

Spain
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer

HER2 Positive Early or Locally Advanced Breast Cancer

Czechia
SOLTI Breast Cancer Research Group
Roche Pharma AG

Recruiting

Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients (IPATHER)

Metastatic Breast Cancer

Spain
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Endometrial Serous Adenocarcinoma | Uterine Corpus Carcinosarcoma

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer (FeDeriCa)

Early Breast Cancer

France, Spain, United States, Korea, Republic of, Canada, United Kingdom, Argentina, Belgium, Germany, Italy, Taiwan, Thailand, Japan, Brazil, Mexico, Czechia, Poland, Russian Federation, Ukraine
Fudan University

Recruiting

Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment

Breast Cancer

China
Fudan University

Not yet recruiting

Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study

Metastatic Colorectal Cancer
Genentech, Inc.

Completed

A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Hoffmann-La Roche

Active, not recruiting

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

HER2-positive Early Breast Cancer

China
Pfizer

Completed

A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)

Healthy

United States
MedSIR
Hoffmann-La Roche

Not yet recruiting

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer (DEMETHER)

HER2-positive Breast Cancer
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | HER2-Positive Breast Carcinoma | Hormone Receptor-Positive Breast Carcinoma

United States, Puerto Rico
Novartis Pharmaceuticals

Active, not recruiting

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation (EPIK-B2)

Advanced HER2+Breast Cancer

Belgium, France, China, Italy, Spain, Malaysia, United States, Turkey
AC Camargo Cancer Center

Recruiting

Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer (HER2Cell)

Breast Neoplasms | HER2-positive Breast Cancer | Circulating Tumor Cell

Brazil
Dana-Farber Cancer Institute
Genentech, Inc.; Eisai Inc.

Terminated

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

Metastatic Breast Cancer | HER2-positive Breast Cancer

United States
QuantumLeap Healthcare Collaborative

Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)

Breast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer

United States
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline; Genentech, Inc.; Susan G. Komen Breast Cancer Foundation

Completed

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

Breast Neoplasms

United States
Dana-Farber Cancer Institute
Johns Hopkins University; Translational Breast Cancer Research Consortium

Not yet recruiting

The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Breast Cancer | HER2-positive Breast Cancer | Stage IV Breast Cancer | Breast Cancer Female | Breast Cancer Metastatic | Estrogen Receptor-positive Breast Cancer

United States
The Methodist Hospital Research Institute
AstraZeneca

Recruiting

Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer (DTP)

Breast Cancer

United States
AstraZeneca
Daiichi Sankyo

Active, not recruiting

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Breast Cancer; HER2-positive; Metastatic

United States, Belgium, Canada, Denmark, Italy, Spain, Hungary, Taiwan, Turkey, France, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, United Kingdom, China, South Africa, Israel, Russian Federation, Argentina, ... and more
Hoffmann-La Roche

Active, not recruiting

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

Solid Tumor

Korea, Republic of, China, France, Portugal, Spain, Brazil, Germany, Italy, Peru, Russian Federation, Japan, Ukraine, Costa Rica, Mexico, Poland
Henan Cancer Hospital

Recruiting

Comparing the Efficacy of Nab-PHP and TCbHP in Neoadjuvant Therapy for HER2 Positive Operable Breast Cancer

Breast Cancer,Her2 Positive

China
Henan Cancer Hospital

Withdrawn

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Breast Cancer | HER2-positive Breast Cancer

China
Agendia
University of South Florida; University of Miami; University of Oklahoma; Ohio... and other collaborators

Completed

MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I (MINT)

Breast Cancer

United States
Weill Medical College of Cornell University
Gilead Sciences

Terminated

Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma

Follicular Lymphoma

United States
Biocon Biologics UK Ltd

Not yet recruiting

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer

HER2-positive Breast Cancer

China
University of Washington
United States Department of Defense

Recruiting

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Unresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast Carcinoma

United States, Canada
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

First-line Treatment | HER2-positive Metastatic Breast Cancer

China
Memorial Sloan Kettering Cancer Center
Hoffmann-La Roche; Genentech, Inc.; Hartford HealthCare

Active, not recruiting

Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy

Metastatic HER2-Positive Breast Cancer

United States
UNICANCER
Seagen Inc.; ARCAGY/ GINECO GROUP

Recruiting

Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer (InTTercePT)

Metastatic Breast Cancer With a Isolated Brain Progression

France
Peking University Cancer Hospital & Institute

Recruiting

Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC

Breast Neoplasm Female

China
Shanghai Henlius Biotech

Completed

Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta in Healthy Chinese Male Subjects

Healthy Male Volunteers

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

HER2-positive Breast Cancer

China
Medstar Health Research Institute
Genentech, Inc.

Completed

Cardiac Safety Study in Patients With HER2 + Breast Cancer (SAFE-HEaRt)

Left Ventricular Function Systolic Dysfunction | HER2 Positive Breast Cancer

United States
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

Breast Cancer

Spain, France, United States, United Kingdom
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Synta Pharmaceuticals Corp.; New York University...

Completed

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Genentech, Inc.; Translational Breast Cancer Research Consortium

Active, not recruiting

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

Breast Cancer

United States
Qamar Khan

Recruiting

Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer (HERMET)

HER2-positive Breast Cancer

United States
Swiss Group for Clinical Cancer Research

Completed

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

Metastatic Breast Cancer

France, Switzerland, Netherlands, Germany
Zydus Lifesciences Limited

Not yet recruiting

A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)

Metastatic Breast Cancer
Gruppo Oncologico Italiano di Ricerca Clinica
Mipharm SpA; Temas srl; Clirest s.r.l.; University Hospital of Parma: Department... and other collaborators

Unknown

Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients (IMMUN-HER)

Cancer, Breast

Italy
Hoffmann-La Roche

Completed

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Breast Cancer

Spain, United Kingdom, Belgium, Austria, Brazil, France, Germany, Hungary, Italy, Thailand, Korea, Republic of, Hong Kong, Romania, Canada, Argentina, Czechia, Peru, Estonia, Mexico, Poland, Russian Federation, Croatia, Netherlands
The Netherlands Cancer Institute
Roche Pharma AG; Borstkanker Onderzoek Groep

Active, not recruiting

Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 (TRAIN-2)

Breast Cancer | HER2 Positive

Netherlands

Search clinical trials for: Pertuzumab, trastuzumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations